SourceOne Partners with Nutri Pharmaceuticals in Powder Technology
SourceOne (Chicago) has partnered with Nutri Pharmaceuticals Research (Las Vegas) to develop powder forms of Source’s products with the hopes to broaden the company’s appeal in the nutritional market.
SourceOne (Chicago) has partnered with Nutri Pharmaceuticals Research (Las Vegas) to develop powder forms of Source’s products with the hopes to broaden the company’s appeal in the nutritional market.
Both companies “share the same vision for delivering greater value and broader functionality of exceptional health and wellness ingredients and formulas through innovative application technology. We like to say that we transform good ingredients into great ingredients,” said NPRI CEO, Godfrey Yew.
This new partnership will allow SourceOne to alter the form of products like CoQsource Coenzyme Q10 and OmegaChoice Concentrated Omega-3 Essential Fatty Acids (EFAs) in free-flowing powders, using NPRI’s oil-to-powder technology, according to Jesse Lopez, SourceOne CEO.
“The synergies created by these partnerships are directly and immediately applicable to SourceOne ingredients and formulas in various forms and concentrations,” said Lopez.
GC Rieber VivoMega uses AI platform from Intelecy to boost efficiency, quality, and sustainability
August 26th 2024According to the company’s announcement, the AI platform is able to identify real-time deviations or anomalies in GC Rieber VivoMega’s processing facilities and report them via a cloud-based, comprehensive, centralized system.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
